Assembly Biosciences, Inc. (ASMB) Reaches New 1-Year High at $34.82
Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $34.82 and last traded at $34.97, with a volume of 72,896 shares. The stock had previously closed at $33.52.
A number of analysts have recently issued reports on ASMB shares. Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. BidaskClub upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Friday, August 18th. Finally, Zacks Investment Research downgraded shares of Assembly Biosciences from a “hold” rating to a “sell” rating in a report on Monday, August 14th.
The stock has a 50 day moving average price of $26.13 and a 200 day moving average price of $24.08. The stock’s market capitalization is $606.35 million.
Several institutional investors and hedge funds have recently made changes to their positions in ASMB. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Assembly Biosciences during the first quarter worth approximately $122,000. FNY Partners Fund LP acquired a new position in Assembly Biosciences during the first quarter worth approximately $140,000. Nationwide Fund Advisors acquired a new position in Assembly Biosciences during the second quarter worth approximately $161,000. Parametric Portfolio Associates LLC increased its position in Assembly Biosciences by 13.6% during the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 1,203 shares during the last quarter. Finally, Legal & General Group Plc acquired a new position in Assembly Biosciences during the second quarter worth approximately $212,000. 72.27% of the stock is currently owned by institutional investors and hedge funds.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Stock Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related stocks with our FREE daily email newsletter.